JOP20220058A1 - بروتينات اندماج علاجية - Google Patents
بروتينات اندماج علاجيةInfo
- Publication number
- JOP20220058A1 JOP20220058A1 JOP/2022/0058A JOP20220058A JOP20220058A1 JO P20220058 A1 JOP20220058 A1 JO P20220058A1 JO P20220058 A JOP20220058 A JO P20220058A JO P20220058 A1 JOP20220058 A1 JO P20220058A1
- Authority
- JO
- Jordan
- Prior art keywords
- acute
- fusion proteins
- chronic
- therapeutic fusion
- organ
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 206010038687 Respiratory distress Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000009692 acute damage Effects 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000009693 chronic damage Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/025—Services making use of location information using location based information parameters
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/029—Location-based management or tracking services
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Telephone Function (AREA)
Abstract
يتعلق الاختراع الحالي ببروتينات اندماج مناسبة للاستخدام كدواء أو أداة بحث. قد تتضمن الاستخدامات العلاجية لبروتينات الاندماج الوقاية أو العلاج من الالتهاب الحاد أو المزمن واضطرابات الأعضاء والأوعية الدموية الدقيقة التي يحثها الجهاز المناعي، على سبيل المثال، إصابة الكلى الحادة، احتشاء عضلة القلب الحاد، مرض تليفي بسبب الضائقة التنفسية الحادة أو الانسداد الرئوي المزمن وإصابات الأعضاء الأخرى الناتجة عن إصابة رضحية بالأنسجة وإصابة حادة ومزمنة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19196045 | 2019-09-06 | ||
PCT/IB2020/058251 WO2021044361A1 (en) | 2019-09-06 | 2020-09-04 | Therapeutic fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220058A1 true JOP20220058A1 (ar) | 2023-01-30 |
Family
ID=67875416
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0055A JOP20220055A1 (ar) | 2019-09-06 | 2020-09-04 | بروتينات اندماج علاجية |
JOP/2022/0058A JOP20220058A1 (ar) | 2019-09-06 | 2020-09-04 | بروتينات اندماج علاجية |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0055A JOP20220055A1 (ar) | 2019-09-06 | 2020-09-04 | بروتينات اندماج علاجية |
Country Status (20)
Country | Link |
---|---|
US (3) | US20230220048A1 (ar) |
EP (3) | EP4025237A1 (ar) |
JP (3) | JP2022547050A (ar) |
KR (3) | KR20220058586A (ar) |
CN (3) | CN114341194A (ar) |
AR (2) | AR119905A1 (ar) |
AU (3) | AU2020343926A1 (ar) |
BR (2) | BR112022003762A2 (ar) |
CA (3) | CA3152990A1 (ar) |
CO (2) | CO2022002567A2 (ar) |
CR (2) | CR20220089A (ar) |
CU (2) | CU20220015A7 (ar) |
EC (2) | ECSP22016180A (ar) |
IL (3) | IL290618A (ar) |
JO (2) | JOP20220055A1 (ar) |
MX (2) | MX2022002638A (ar) |
PE (2) | PE20220401A1 (ar) |
TW (2) | TW202122414A (ar) |
WO (3) | WO2021044362A1 (ar) |
ZA (2) | ZA202201827B (ar) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022509445A (ja) * | 2018-10-25 | 2022-01-20 | ネクセル カンパニー,リミテッド | 線維症を治療又は予防するための組成物及び方法 |
EP4326307A1 (en) * | 2021-04-22 | 2024-02-28 | Biolegend, Inc. | Phosphatidylserine binding agents for the detection and depletion of phosphatidylserine positive cells |
CN114288386B (zh) * | 2022-01-25 | 2023-12-12 | 华中科技大学同济医学院附属协和医院 | Del-1作为炎症性肠病新的生物标志物及治疗药物应用 |
WO2024080854A1 (en) * | 2022-10-14 | 2024-04-18 | Illimis Therapeutics, Inc. | Fusion molecule and method for treating immunological diseases |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
AU2006243905B2 (en) | 2005-05-13 | 2011-09-01 | The Feinstein Institute For Medical Research | Milk fat globule epidermal growth factor-factor VIII and sepsis |
CN101511866A (zh) * | 2006-09-08 | 2009-08-19 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
EP2215264B1 (en) * | 2007-11-15 | 2015-04-01 | The Feinstein Institute for Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
EP3421491A3 (en) | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Albumin variants |
JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
WO2012149254A2 (en) | 2011-04-28 | 2012-11-01 | The Feinstein Institute For Medical Research | Mfg-e8 and uses thereof |
US8822417B2 (en) | 2011-05-05 | 2014-09-02 | Novozymes Biopharma DIC A/S | Albumin variants |
US20140302027A1 (en) * | 2011-09-26 | 2014-10-09 | University Of Louisville Research Foundation, Inc. | Methods of treating periodontal inflammation and periodontal bone loss |
BR112015010318A2 (pt) | 2012-11-08 | 2017-08-22 | Albumedix As | Variantes de albumina |
AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
SG11201602289WA (en) | 2013-08-23 | 2016-05-30 | Riken | Polypeptide exhibiting fluorescent properties, and utilization of same |
KR102385120B1 (ko) * | 2014-03-31 | 2022-04-12 | 한미약품 주식회사 | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 |
CN106537795B (zh) * | 2014-03-31 | 2021-10-01 | 英国电讯有限公司 | 数据通信 |
WO2015175512A1 (en) * | 2014-05-15 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of regulating bone resorption |
KR20170013621A (ko) | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Milk fat globule-EGF factor(MFG-E8)을 이용한 조직섬유화 예방 또는 치료용 조성물 |
WO2018158719A1 (en) * | 2017-03-02 | 2018-09-07 | Novartis Ag | Engineered heterodimeric proteins |
US11028139B2 (en) | 2017-05-17 | 2021-06-08 | Nexel Co., Ltd. | Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same |
JP2022509445A (ja) | 2018-10-25 | 2022-01-20 | ネクセル カンパニー,リミテッド | 線維症を治療又は予防するための組成物及び方法 |
-
2020
- 2020-09-04 EP EP20768408.5A patent/EP4025237A1/en active Pending
- 2020-09-04 KR KR1020227010892A patent/KR20220058586A/ko unknown
- 2020-09-04 CR CR20220089A patent/CR20220089A/es unknown
- 2020-09-04 JO JOP/2022/0055A patent/JOP20220055A1/ar unknown
- 2020-09-04 CU CU2022000015A patent/CU20220015A7/es unknown
- 2020-09-04 CR CR20220096A patent/CR20220096A/es unknown
- 2020-09-04 CN CN202080061452.4A patent/CN114341194A/zh active Pending
- 2020-09-04 CA CA3152990A patent/CA3152990A1/en active Pending
- 2020-09-04 EP EP20768410.1A patent/EP4025239A1/en active Pending
- 2020-09-04 US US17/640,295 patent/US20230220048A1/en active Pending
- 2020-09-04 AU AU2020343926A patent/AU2020343926A1/en active Pending
- 2020-09-04 KR KR1020227010907A patent/KR20220058588A/ko unknown
- 2020-09-04 JP JP2022514568A patent/JP2022547050A/ja active Pending
- 2020-09-04 WO PCT/IB2020/058252 patent/WO2021044362A1/en unknown
- 2020-09-04 BR BR112022003762A patent/BR112022003762A2/pt unknown
- 2020-09-04 CU CU2022000016A patent/CU20220016A7/es unknown
- 2020-09-04 EP EP20768409.3A patent/EP4025238A1/en active Pending
- 2020-09-04 CN CN202080061631.8A patent/CN114302896A/zh active Pending
- 2020-09-04 CN CN202080061624.8A patent/CN114341195A/zh active Pending
- 2020-09-04 PE PE2022000365A patent/PE20220401A1/es unknown
- 2020-09-04 PE PE2022000372A patent/PE20221051A1/es unknown
- 2020-09-04 AU AU2020343512A patent/AU2020343512A1/en active Pending
- 2020-09-04 AR ARP200102483A patent/AR119905A1/es unknown
- 2020-09-04 AU AU2020340618A patent/AU2020340618A1/en active Pending
- 2020-09-04 KR KR1020227010891A patent/KR20220058585A/ko unknown
- 2020-09-04 WO PCT/IB2020/058250 patent/WO2021044360A1/en active Application Filing
- 2020-09-04 WO PCT/IB2020/058251 patent/WO2021044361A1/en active Application Filing
- 2020-09-04 US US17/640,293 patent/US20230265160A1/en active Pending
- 2020-09-04 TW TW109130528A patent/TW202122414A/zh unknown
- 2020-09-04 MX MX2022002638A patent/MX2022002638A/es unknown
- 2020-09-04 JP JP2022514843A patent/JP2022547111A/ja active Pending
- 2020-09-04 US US17/640,291 patent/US20230308835A1/en active Pending
- 2020-09-04 CA CA3152500A patent/CA3152500A1/en active Pending
- 2020-09-04 MX MX2022002637A patent/MX2022002637A/es unknown
- 2020-09-04 JO JOP/2022/0058A patent/JOP20220058A1/ar unknown
- 2020-09-04 AR ARP200102479A patent/AR119902A1/es unknown
- 2020-09-04 BR BR112022003745A patent/BR112022003745A2/pt unknown
- 2020-09-04 CA CA3152499A patent/CA3152499A1/en active Pending
- 2020-09-04 JP JP2022514570A patent/JP2022547051A/ja active Pending
- 2020-09-07 TW TW109130667A patent/TW202122415A/zh unknown
-
2022
- 2022-02-11 ZA ZA2022/01827A patent/ZA202201827B/en unknown
- 2022-02-11 ZA ZA2022/01828A patent/ZA202201828B/en unknown
- 2022-02-14 IL IL290618A patent/IL290618A/en unknown
- 2022-02-16 IL IL290660A patent/IL290660A/en unknown
- 2022-02-16 IL IL290675A patent/IL290675A/en unknown
- 2022-03-03 EC ECSENADI202216180A patent/ECSP22016180A/es unknown
- 2022-03-03 CO CONC2022/0002567A patent/CO2022002567A2/es unknown
- 2022-03-03 CO CONC2022/0002545A patent/CO2022002545A2/es unknown
- 2022-03-04 EC ECSENADI202216558A patent/ECSP22016558A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202201828B (en) | Therapeutic fusion proteins | |
WO2017087608A8 (en) | Modulators of ror-gamma | |
WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
WO2015139051A3 (en) | Nanocarriers and their processing for diagnostics and therapeutics | |
EP4252755A3 (en) | Therapeutic compounds | |
MX2020012034A (es) | Inhibidores de furina. | |
JP2016509011A5 (ar) | ||
WO2016109217A3 (en) | Btk inhibitors | |
WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
MX2017012272A (es) | Solucion para inhalacion de tiotropio para nebulizacion. | |
MX2018005676A (es) | Composiciones y metodos para regeneracion de disco degenerativo. | |
RU2017145271A (ru) | Терапевтическое средство для фиброза | |
WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
WO2018151562A3 (ko) | Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 | |
WO2021074649A3 (en) | Methods of promoting scfa production by gut microbiota | |
WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
WO2017049082A3 (en) | Compositions comprising pregnancy specific glycoproteins and methods of use thereof | |
ZA202200331B (en) | Naltrexone formulation | |
WO2017081218A3 (en) | Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3 | |
JP2018043942A5 (ar) | ||
WO2019245513A3 (en) | A combination comprising fingolimod and amantadine | |
WO2020117151A3 (en) | A combination comprising fingolimod and modafinil |